A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3032 Following Single Intravenous Administration in Healthy Subjects
Latest Information Update: 18 Oct 2024
At a glance
- Drugs SHR-3032 (Primary)
- Indications Transplant rejection
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Guangdong Hengrui Pharmaceutical
- 15 Oct 2024 Status changed from recruiting to completed.
- 03 Dec 2023 Status changed from not yet recruiting to recruiting.
- 26 Oct 2023 New trial record